Lv6
3150 积分 2026-02-02 加入
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies
2天前
已完结
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies
5天前
已完结
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact
5天前
已完结
Noncanonical and mortality-defining toxicities of CAR T cell therapy
6天前
已完结
Current understanding and management of CAR T cell-associated toxicities
7天前
已完结
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders
7天前
已完结
Critical care considerations of chimeric antigen receptor (CAR) T-cell therapy
7天前
已完结
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
12天前
已完结
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
1个月前
已完结
European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma
1个月前
已完结
皖公网安备34019202002308
